Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page
- Check2 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study content, signaling restricted access to this ClinicalTrials.gov record. The additions reflect the error page structure (doctype, meta, 403 title) and footer information showing the site revision.SummaryDifference19%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page revision was updated to v3.6.6, indicating a small platform-level update. It does not change trial details, eligibility criteria, outcomes, or other substantive content on the study page.SummaryDifference0.1%

- Check30 days agoChange DetectedThe study's external identifiers now include an NIH funding reference for 2017, adding funding attribution to the record.SummaryDifference0.1%

- Check44 days agoChange DetectedThe page now displays a new revision version (v3.6.5) replacing the previous one, indicating a release update. This update pertains to the site's software layer rather than the clinical trial data or public text.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page now shows a new revision tag 'Revision: v3.6.4' replacing the previous 'Revision: v3.6.3'. This indicates a minor update to the study record page's metadata rather than a change to the study content.SummaryDifference0.1%

- Check80 days agoChange DetectedFooter revision updated from v3.6.2 to v3.6.3, indicating a new page build. The change does not modify study information or user-facing content.SummaryDifference0.1%

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.